{"id":"W2951994857","doi":"10.1002/hon.52_2629","title":"FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority","funders":"Università degli Studi di Perugia; Hospital de Clínicas de Porto Alegre; Monash University; F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Minimal residual disease; Obinutuzumab; Hazard ratio; Clinical endpoint; Population; Surrogate endpoint; Oncology; Venetoclax; Progression-free survival; Confidence interval; Surgery; Chronic lymphocytic leukemia; Randomized controlled trial; Bone marrow; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009445,0.0003086748,0.0008040024,0.0001489952,0.0001867724,0.000422882,0.0003383036,0.0003827568,0.002647516],"category_scores_gemma":[0.0005880948,0.0001484869,0.0005052817,0.0002388271,0.0003042192,0.0003031869,0.0001742633,0.0006089084,0.0001905668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005118049,"about_ca_system_score_gemma":0.0006873587,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000674705,"about_ca_topic_score_gemma":0.002450366,"domain_scores_codex":[0.9997378,0.0001264506,0.00002032167,0.00003863119,0.0000294584,0.00004726585],"domain_scores_gemma":[0.9996524,0.00008913214,0.0001146553,0.00002076653,0.00001425827,0.0001087617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8003067,0.007585611,0.03867693,0.0007804955,0.001274433,0.0001516229,0.0001231881,0.002276625,0.02167985,0.0001468156,0.001384653,0.125613],"study_design_scores_gemma":[0.3710956,0.441177,0.1713781,0.0001963382,0.001755353,0.0007578959,0.00009443232,0.001884012,0.005896965,0.0002581146,0.005460096,0.00004610096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964674,0.002507935,0.0001164337,0.00006893038,0.00002196522,0.000133263,0.0001934069,0.00001035719,0.0004803663],"genre_scores_gemma":[0.9982399,0.0006216738,0.0002151978,0.0001002623,0.0000432766,0.0001318334,0.0003055688,0.000002279424,0.0003399927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002647516,"threshold_uncertainty_score":0.008856833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314273874397396,"score_gpt":0.2757265332305638,"score_spread":0.2625837944865899,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}